Sun Pharmaceuticals on Saturday said that it would come up with a revised guidance on its performance in the wake of action taken by the USFDA against Taraco Pharma, its US-based subsidiary.

The USFDA had seized the entire stock of drugs manufactured at the Michigan facility of the company for failing to meet high manufacturing standards.

Speaking to analysts through a conference call, Sun Pharma's Chairman and Managing Director, Dilip Sanghavi, said "as soon as we have clarity, we will give our revised guidance."

He said that the USFDA action was not the result of any new legislation but only the enforcement of existing laws more forcefully due to some instances which affected US citizens.

Sanghavi clarified that the problem was specific to Taraco and Sun Pharma's other facilities inspected by the FDA do not have any issues.

He said that action against Taraco was under a Court order and the company would interact with FDA through lawyers to get the issue resolved.

He indicated that the FDA action might affect the company in the short-term but there would not be any impact in the medium-to-long-term.